1 / 29

Healthcare Reform and Medicare Part D

Healthcare Reform and Medicare Part D. Dsih-lang Liu, FSA, MAAA Centers for Medicare & Medicaid Services. Medicare Part D Benefits. Prescription drug benefit in Medicare in Medicare Modernization Act passed on Dec. 8, 2003

keaton
Télécharger la présentation

Healthcare Reform and Medicare Part D

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Healthcare Reform and Medicare Part D Dsih-lang Liu, FSA, MAAA Centers for Medicare & Medicaid Services

  2. Medicare Part D Benefits • Prescription drug benefit in Medicare in Medicare Modernization Act passed on Dec. 8, 2003 • Optional coverage with subsidized premiums started on Jan. 1, 2006 • Eligibility: entitled to A or enrolled in B

  3. CY 2006 Benefit Structure • $250 deductible • 25% coinsurance up to $2,250 initial coverage limit (ICL) • Coverage gap (donut hole) • $3,600 true out-of-pocket (TrOOP) catastrophic limit (=$5,100 incurred costs/threshold) • Beneficiary pays greater of $2 generic/$5 brand or 5% coinsurance above catastrophic threshold • TrOOP excludes reimbursement by insurance, employers etc.

  4. Out - of Initial Coverage - Threshold Limit Total Catastrophic Pocket Coverage Spending $250 $ 2,250 $ 5,100 75% Plan Pays Coverage Gap 80% Reinsurance $ + Deductible 95% ? 25% Coinsurance $3,600 TrOOP 15% Plan Pays 5% Coinsurance Medicare Pays Reinsurance Beneficiary Liability Direct Subsidy Beneficiary Premium

  5. CY 2011 Benefit Structure • $310 deductible • $2,840 ICL • $4,550 OOP catastrophic limit • Threshold varies by beneficiary • $6,447.50 if 100% brand in gap • $6,719.03 if 100% generic in gap

  6. Part D Coverage • Individual plans • Prescription drug plans (PDPs) • Medicare Advantage prescription drug plans (MA-PDs) • Employer group waiver plans (EGWPs) • Retiree drug subsidy (RDS) plans • Creditable coverage

  7. Benefit Options (PDPs & PDs) • Standard • Actuarial equivalent • Basic alternative • Enhanced alternative

  8. Payments to Plans • Direct subsidy: risk adjusted • Beneficiary premiums per plan bids • Reinsurance advance payments • Low-income cost sharing (LICS) advance payments • Low-income premium subsidy (LIPS) • Year end reconciliation: reinsurance, LICS and risk corridor adjustments

  9. Employer Group Waiver Plans • Encourage Part D participation • Do not submit bids • Benefits must be at least as generous as standard Part D benefit

  10. Retiree Drug Subsidy Plans • 28% subsidy between $310 and $6,300 in 2011 • Updated similarly to the Part D benefit parameters • Tax exempt through 2012 • Plans must pass gross and net tests • 6.6 million enrollees in 2009

  11. Creditable Coverage • Other qualifying prescription drug coverage • Working aged • VA/DOD • Indian Health Services (IHS) • Not subject to late enrollment penalty

  12. Healthcare Reform:Patient Protection and Affordable Care Act (ACA) • Enacted Mar. 2010

  13. ACA Effects on Part D • Closing the coverage gap • Income related premiums (IRP) • Eliminate tax exemption for RDS in 2013 • LIS benchmark calculation methodology • De minimis • Protected drug classes • Waste reduction in long term care (LTC) facilities • TrOOP for IHS and AIDS Drug Assistance Program (ADAP) • Pathway for follow-on biologics (FOBs) • Independent Payment Advisory Board (IPAB)

  14. Closing the Coverage Gap • $250 rebate in 2010 if exceeds ICL • 50% brand discount starting Jan. 2011 • Not applied to dispensing fee • Discount is considered TrOOP • Slower growth in catastrophic threshold • Transitioning in 2020 to • Brand: plan 25%, bene 25%, PhRma 50% • Generic: plan 75%, bene 25%

  15. Closing the Coverage Gap (cont.)

  16. Closing the Coverage Gap (cont.) • No 50% brand discount for • RDS beneficiaries • LIS beneficiaries

  17. Income Related Premiums • Same income threshold as Part B IRP • Beneficiaries will pay higher premiums; i.e. lower direct subsidies • Expect some portion of beneficiaries to drop coverage • Threshold is frozen through 2019 • EGWPs subject to IRP

  18. Income Related Monthly Adjustment Amount (IRMAA)

  19. RDS Greatly Disadvantaged • No tax exemption for subsidy • No brand discount • Expenses eligible for 28% subsidy do not increase as donut hole disappears

  20. LIS Benchmark Methodology • 2006-2009: calculated after MA rebate re-allocation • 2010 Demonstration calculated before MA rebate re-allocation • ACA: calculates before MA rebate re-allocation for 2011 and later • Increase the LIPS for most regions

  21. De Minimis • Plans can waive the de minimis premiums to keep LIS beneficiaries • Cannot get new LIS auto-assignees • For 2011, the de minimis amount is $2 • A minor cost for Part D by not re-assigning LIS beneficiaries to lower premium plans • Re-assignments reduced from 1.1 to 0.5 million

  22. Protected Drug Classes • Include all covered Part D drugs in 6 classes: • Anticonvulsants • Antidepressants • Antineoplastics • Antipsychotics • Antiretrovirals • Immunosuppressants for transplant rejection

  23. Protected Drug Classes (cont.) • All drugs in the protected classes must be in formulary • ACA • Codifies the authority for protected classes • Allows for new considerations

  24. Wasteful Reduction in LTC Facilities • 7-day or less dispensing • Applied to brand drugs only • Expect savings on brand drugs • More dispensing fees

  25. TrOOP for ADAP/IHS • Currently, ADAP/IHS not considered TrOOP • ACA: ADAP/IHS will be TrOOP • Beneficiaries will reach catastrophic coverage sooner

  26. Follow-on Biologics • “Generic” version of biologics • Currently there is no approval pathway for FOBs • ACA provides an approval pathway for biologics

  27. Follow-on Biologics (cont.) • Insulin is among the top categories in spending • No impact expected on insulin because it is governed by a different pathway

  28. IPAB to Control Growth • Independent Payment Advisory Board • Starting in 2014 • Recommend spending reduction measures affecting providers and suppliers, including Part D plans • If projected Medicare per capita spending growth exceeds target rate

  29. Questions? dsihlang.liu@cms.hhs.gov

More Related